摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride | 179462-37-4

中文名称
——
中文别名
——
英文名称
(±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride
英文别名
(rac-di-exo)-3-amino-bicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride;(1R,2S,3R,4S)-3-Aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride;(1R,2S,3R,4S)-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid;hydrochloride
(±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride化学式
CAS
179462-37-4
化学式
C8H13NO2*ClH
mdl
——
分子量
191.658
InChiKey
GVGHCTZKPYWADE-BZUDZRPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.87
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    63.3
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    WO2008/124450
    摘要:
    公开号:
  • 作为产物:
    描述:
    N-(Chlorosulfonyl)-exo-3-aza-4-ketotricyclo<4.2.1.02,5>nonane 在 盐酸 、 sodium hydroxide 、 sodium sulfite 作用下, 以 为溶剂, 生成 (±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride
    参考文献:
    名称:
    Large-Scale Syntheses of FMOC-Protected Non-Proteogenic Amino Acids:  Useful Building Blocks for Combinatorial Libraries
    摘要:
    Convenient and reliable large-scale procedures for the protection of various amino acids with N-(9-fluorenyimethoxycarbonyl)oxysuccinimide (FMOC-OSu) are described. Commercially available 4-aminomethylbenzoic acid and trans-4-(aminomethyl)cyclohexanecarboxylic acid were converted into their corresponding FMOC-derivatives in excellent yields without the need for an extractive workup. In addition, FMOC-cis-beta -amino acids were also prepared, employing a [2 + 2]-cycloaddition strategy between a cyclic olefin and N-chlorosulfonyl isocyanate (CSI). The resulting N-chlorosulfonyl fl-lactams were reduced to the parent beta -lactams with sodium sulfite and then converted to the cis-fi-amino acid hydrochlorides by exposure to aqueous hydrochloric acid. The resulting cis-fi-amino acids were converted to their FMOC-derivatives under conditions similar to those developed for the commercially available amino acids. Differences in the conditions employed between these beta -amino acids and the commercial derivatives were observed, primarily in the nature of the base required for the reaction. A possible rationale for the differences in behavior is described. These FMOC-amino acid derivatives are valuable intermediates for the solid-phase synthesis of combinatorial libraries.
    DOI:
    10.1021/op010204f
点击查看最新优质反应信息

文献信息

  • [EN] A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS<br/>[FR] PROCÉDÉ D'INHIBITION DU VIRUS DE L'HÉPATITE C PAR COMBINAISON D'UNE 5,6-DIHYDRO-1H-PYRIDIN-2-ONE ET D'UN OU PLUSIEURS COMPOSÉS ANTIVIRAUX SUPPLÉMENTAIRES
    申请人:ANADYS PHARMACEUTICALS INC
    公开号:WO2010042834A1
    公开(公告)日:2010-04-15
    The invention is directed to a method of treating infections by hepatitis C virus by administering N-3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-l,4-dihydro-lλ6- benzo[l,2,4]thiadiazin-7-yl} -methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.
    本发明涉及一种治疗乙型肝炎病毒感染的方法,通过给予N-3-[(1R,2S,7R,8S)-3-(4-氟苯基)-6-羟基-4-氧代-3-氮杂三环[6.2.1.02,7]十一碳-5-烯-5-基]-1,1-二氧代-1,4-二氢-1λ6-苯并[1,2,4]噻二唑-7-基}-甲磺酰胺以及一个或多个附加的抗病毒化合物或含有此类化合物的药物组合物。
  • [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS
    申请人:Ruebsam Frank
    公开号:US20090306057A1
    公开(公告)日:2009-12-10
    The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    这项发明涉及[1,2,4]噻二嗪1,1-二氧化物化合物和含有这种化合物的药物组合物,可用于治疗丙型肝炎病毒感染。
  • [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID
    申请人:Freddo James L.
    公开号:US20120316156A1
    公开(公告)日:2012-12-13
    The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a [1,2,4]thiadiazine 1,1-dioxide compound.
    本发明描述了[1,2,4]噻二嗪1,1-二氧化物化合物及其药用可接受盐,这些化合物在降低需要的患者的血清尿酸方面是有用的,包括向患者投予治疗或预防有效量的[1,2,4]噻二嗪1,1-二氧化物化合物。
  • 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS
    申请人:Tran Chinh V.
    公开号:US20100034773A1
    公开(公告)日:2010-02-11
    The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    该发明涉及5,6-二氢-1H-吡啶-2-酮化合物和含有这种化合物的药物组合物,用于治疗丙型肝炎病毒感染。
  • [EN] 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE<br/>[FR] DÉRIVÉS D'ACIDE 4-(2-FLUORO-4-MÉTHOXY-5-3-(((1-MÉTHYLCYCLOBUTYLE)MÉTHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL) CARBAMOYL)PHÉNOXY)-1-MÉTHYLCYCLOHEXANE-1-CARBOXYLIQUE ET COMPOSÉS SIMILAIRES COMME MODULATEURS DE RXFP1 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
    申请人:ASTRAZENECA AB
    公开号:WO2022122773A1
    公开(公告)日:2022-06-16
    The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl) carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as RXFP1 modulators for the treatment of heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The present invention also relates to crystalline forms of such compounds. An exemplary compound is e.g. (A).
    本发明涉及4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基)双环[2.2.1]庚烷-2-基)氨基苯氧基)-1-甲基环己烷-1-羧酸衍生物及类似化合物,其为RXFP1调节剂,用于治疗心力衰竭、保留射血分数的心力衰竭、中等射血分数的心力衰竭、降低射血分数的心力衰竭、慢性肾脏病和急性肾损伤。本发明还涉及这种化合物的晶体形式。一个示例化合物是例如(A)。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物